North America Anti-Viral Therapies Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type (Generic Drugs and Branded Drugs), Mechanism of Action (Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others), and Application (HIV, Hepatitis, Virus Influenza, Herpes, and Other Applications), and Country

Code: TIPRE00014167 | Pages: 117 | Industry: Pharmaceuticals | Date: Sep 2020 | Type: Regional

Market Introduction

Antiviral therapy is one of the most exciting branches of virology. These therapies are based on several strategies—direct-acting antivirals target viral proteins, enzymes, or nucleic acids; passive antibodies neutralize circulating viruses; and several other antivirals target cellular proteins or processes essential for viral replication.


Get more information on this report :



Market Overview and Dynamics

The North America anti-viral therapies market is expected to reach US$ 31,092.80 million by 2027 from US$ 16,312.45 million in 2019; it is anticipated to grow at a CAGR of 8.5% during 2020–2027. The growth of the market is attributed to the increasing prevalence of viral diseases and outbreak of COVID-19 pandemic, surging R&D expenditures by pharmaceutical companies, and rising government support for research activities and clinical trials. However, the high cost of drug development obstructs the growth of the market to a certain extent.

Key Market Segments

In terms of type, the branded drugs segment accounted for a larger share of the North America anti-viral therapies market in 2019. In terms of mechanism of action, the nucleotide polymerase inhibitors segment accounted for the largest share of the North America anti-viral therapies market in 2019. In terms of application, the HIV segment accounted for the largest share of the North America anti-viral therapies market in 2019.

Major Sources and Companies Listed

Several major primary and secondary sources associated with the North America anti-viral therapies market report are the World Health Organization (WHO), Pharmaceutical Research and Manufacturers of America (PhRMA),Centers of Disease Control and Prevention (CDC), and others.

Reasons to Buy Report

  • It provides understanding of the North America anti-viral therapies market landscape and identifies anti-viral therapies market segments that are most likely to guarantee a strong return.
  • It guides stay ahead of the race by comprehending the ever-changing competitive market landscape
  • It helps efficiently plan merger and acquisition, and partnership deals in the anti-viral therapies market in North America by identifying market segments with the most promising probable sales
  • It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of the market performance of various segments.
  • It provides revenue forecast of the market based on various segments for the period from 2019 to 2027.

NORTH AMERICA ANTI-VIRAL THERAPIESMARKET SEGMENTATION

By Type

  • Branded Drugs
  • Generic Drugs

 

By Mechanism of Action

  • Nucleotide Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Others

 

By Application

  • HIV
  • Hepatitis
  • Virus Influenza
  • Herpes
  • Others 

 

By Country

  • US
  • Canada
  • Mexico

 

Company Profiles

  • Abbott
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Johnson and Johnson Services, Inc
  • Merck & Co., Inc
  • Gilead Sciences, Inc.

1.          Introduction

1.1        Scope of the Study

1.2        The Insight Partners Research Report Guidance

1.3        Market Segmentation

1.3.1        North America Anti-viral therapies Market – By Type

1.3.2        North America Anti-Viral Therapies Market – By Mechanism of Action

1.3.3        North America Anti-Viral Therapies Market– By Application

1.3.4        North America Anti-Viral Therapies Market – By Country

2.          North America Anti-Viral Therapies Market – Key Takeaways

3.          Research Methodology

3.1        Coverage

3.2        Secondary Research

3.3        Primary Research

4.          North America Anti-Viral Therapies Market – Market Landscape

4.1        Overview

4.2        PEST Analysis

4.2.1        Anti-Viral Therapies Market - North America PEST Analysis

4.3        Expert Opinion

5.          North America Anti-Viral Therapies Market -  Key Market Dynamics

5.1        Key Market Drivers

5.1.1        Increasing R&D Expenditures in Pharmaceutical Companies

5.1.2        Rising Government Support for Research Activities and Clinical Trials

5.2        Market Restraints

5.2.1        High Cost of Drug Development

5.3        Market Opportunities

5.3.1        Strong Pipeline of Anti-Viral Drugs

5.4        Future Trends

5.4.1        Growing Emphasis on Launching Anti-Viral Agents

5.5        Impact analysis

6.          Anti-Viral Therapies Market – North America Analysis

6.1        North America Anti-Viral Therapies Market Revenue Forecasts and Analysis

7.          North America Anti-Viral Therapies Market Analysis and Forecasts To 2027 – By Type

7.1        Overview

7.2        North America Anti-Viral Therapies Market, By Type 2019 & 2027 (%)

7.2.1        North America Anti-Viral Therapies Market Revenue and Forecasts to 2027, By Type (US$ Mn)

7.3        Generic Drugs

7.3.1        Overview

7.3.2        North America Generic Drugs Market Revenue and Forecast to 2027 (US$ Mn)

7.4        Branded Drugs

7.4.1        Overview

7.4.1.1         North America Branded Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

8.          North America Anti-Viral Therapies Market Analysis – By Mechanism of Action

8.1        Overview

8.2        North America Anti-Viral Therapies Market, By Mechanism of Action 2019-2027 (%)

8.2.1        North America Anti-Viral Therapies Market Revenue and Forecasts to 2027, By Mechanism of Action (US$ Mn)

8.3        Nucleotide Polymerase Inhibitor

8.3.1        Overview

8.3.2        North America Nucleotide Polymerase Inhibitor Market Revenue and Forecasts to 2027 (US$ Mn)

8.4        Reverse Transcriptase Inhibitors

8.4.1        Overview

8.4.2        North America Reverse Transcriptase Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)

8.5        Protease Inhibitors

8.5.1        Overview

8.5.2        North America Protease Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)

8.6        Others

8.6.1        Overview

8.6.2        North America Others Market Revenue and Forecasts to 2027 (US$ Mn)

9.          North America Anti-Viral Therapies Market Analysis and Forecasts To 2027 – By Application

9.1        Overview

9.2        North America Anti-Viral Therapies Market, By Application 2019 & 2027 (%)

9.2.1        North America Anti-Viral Therapies Market Revenue and Forecasts to 2027, By Application (US$ Mn)

9.3        HIV

9.3.1        Overview

9.3.2        North America HIV Market Revenue and Forecast to 2027 (US$ Mn)

9.4        Hepatitis

9.4.1        Overview

9.4.2        North America Hepatitis Market Revenue and Forecasts to 2027 (US$ Mn)

9.5        Herpes

9.5.1        Overview

9.5.2        North America Herpes Market Revenue and Forecasts to 2027 (US$ Mn)

9.6        Influenza

9.6.1        Overview

9.6.2        North America Influenza Market Revenue and Forecasts to 2027 (US$ Mn)

9.7        Other Applications

9.7.1        Overview

9.7.2        North America Others Market Revenue and Forecasts to 2027 (US$ Mn)

10.       Anti-Viral Therapies Market Revenue and Forecasts To 2027 – Geographical Analysis

10.1     North America Anti-Viral Therapies Market Revenue and Forecasts To 2027

10.1.1     Overview

10.1.2     North America: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.1.3     North America: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.1.4     North America: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.1.5     North America: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.1.6     North America: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)

10.1.7     US: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.1.7.1       US: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.1.7.2       US: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.1.7.3       US: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.1.7.4       US: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.1.8     Canada: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.1.8.1       Canada: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.1.8.2       Canada: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.1.8.3       Canada: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.1.8.4       Canada: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

10.1.9     Mexico: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.1.9.1       Mexico: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

10.1.9.2       Mexico: Anti-Viral Therapies Market, by Type, 2018–2027 (USD Million)

10.1.9.3       Mexico: Anti-Viral Therapies Market, by Mechanism of Action, 2018–2027 (USD Million)

10.1.9.4       Mexico: Anti-Viral Therapies Market, by Application, 2018–2027 (USD Million)

11.       Impact of COVID-19 Pandemic on North America Anti-viral therapies Market

11.1     North America: Impact Assessment of COVID-19 Pandemic

12.       Company Profiles

12.1     Abbott

12.1.1     Key Facts

12.1.2     Business Description

12.1.3     Products and Services

12.1.4     Financial Overview

12.1.5     SWOT Analysis

12.1.6     Key Developments

12.2     AbbVie Inc.

12.2.1     Key Facts

12.2.2     Business Description

12.2.3     Products and Services

12.2.4     Financial Overview

12.2.5     SWOT Analysis

12.2.6     Key Developments

12.3     Bristol-Myers Squibb Company

12.3.1     Key Facts

12.3.2     Business Description

12.3.3     Products and Services

12.3.4     Financial Overview

12.3.5     SWOT Analysis

12.3.6     Key Developments

12.4     Johnson and Johnson Services, Inc.

12.4.1     Key Facts

12.4.2     Business Description

12.4.3     Products and Services

12.4.4     Financial Overview

12.4.5     SWOT Analysis

12.4.6     Key Developments

12.5     Merck & Co., Inc.

12.5.1     Key Facts

12.5.2     Business Description

12.5.3     Products and Services

12.5.4     Financial Overview

12.5.5     SWOT Analysis

12.5.6     Key Developments

12.6     Gilead Sciences, Inc.

12.6.1     Key Facts

12.6.2     Business Description

12.6.3     Products and Services

12.6.4     Financial Overview

12.6.5     SWOT Analysis

12.6.6     Key Developments

13.       Appendix

13.1     About The Insight Partners

13.2     Glossary of Terms

 

LIST OF TABLES

Table 1.            R&D Investments by Major Pharmaceutical Companies

Table 2.            North America Anti-Viral Therapies Market Revenue and Forecasts To 2027, By Type (US$ Mn)

Table 3.            North America Anti-Viral Therapies Market Revenue and Forecasts To 2027, By Mechanism of Action (US$ Mn)

Table 4.            North America Anti-Viral Therapies Market Revenue and Forecasts To 2027, By Application (US$ Mn)

Table 5.            North America Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 6.            North America Anti-Viral Therapies Market, by Mechanism of Action – Revenue and Forecast to 2027  (USD Million)

Table 7.            North America Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 8.            US Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 9.            US Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)

Table 10.         US Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 11.         Canada Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 12.         Canada Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)

Table 13.         Canada Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 14.         Mexico Anti-Viral Therapies Market, by Type – Revenue and Forecast to 2027 (USD Million)

Table 15.         Mexico Anti-Viral Therapies Market, by Mechanism of Action– Revenue and Forecast to 2027 (USD Million)

Table 16.         Mexico Anti-Viral Therapies Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 17.         Glossary of Terms, Anti-Viral Therapies Market

 

LIST OF FIGURES

Figure 1.          Anti-viral therapies Market Segmentation

Figure 2.          North America Anti-Viral Therapies Market Overview

Figure 3.          Branded Drugs Segment Held Largest Share of Anti-Viral Therapies Market

Figure 4.          US is Expected to Show Remarkable Growth During the Forecast Period

Figure 5.          North America Anti-Viral Therapies Market - Leading Country Markets (US$ Mn)

Figure 6.          Anti-Viral Therapies Market - North America PEST Analysis

Figure 7.          Anti-Viral Therapies Market Impact Analysis of Driver and Restraints

Figure 8.          North America Anti-viral therapies Market – Revenue Forecasts and Analysis – 2019- 2027

Figure 9.          North America Anti-Viral Therapies Market, By Type 2019 & 2027 (%)

Figure 10.        North America Generic Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 11.        North America Branded Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 12.        North America Anti-Viral Therapies Market, by Mechanism of Action 2019 & 2027 (%)

Figure 13.        North America Nucleotide Polymerase Inhibitor Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 14.        North America Reverse Transcriptase Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 15.        North America Protease Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 16.        North America Others Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 17.        North America Anti-Viral Therapies Market, By Application 2019 & 2027 (%)

Figure 18.        North America HIV Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 19.        North America Hepatitis Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 20.        North America Herpes Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 21.        North America Influenza Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 22.        North America Others Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 23.        North America: Anti-Viral Therapies Market, by Key Country – Revenue (2019) (USD Million)

Figure 24.        North America Anti-Viral Therapies Market Revenue and Forecast to 2027 (USD Million)

Figure 25.        North America: Anti-Viral Therapies Market, by Country, 2019 & 2027 (%)

Figure 26.        US: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 27.        Canada: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 28.        Mexico: Anti-Viral Therapies Market – Revenue and Forecast to 2027 (USD Million)

Figure 29.        Impact of COVID-19 Pandemic in North American Country Markets

 

The List of Companies - North America Anti-Viral Therapies Market

  1. Abbott
  2. AbbVie Inc.
  3. Bristol-Myers Squibb Company
  4. Johnson and Johnson Services, Inc
  5. Merck & Co., Inc
  6. Gilead Sciences, Inc.

 

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3000
Site License
$4000
Enterprise License
$5000